Capricor Therapeutics Inc (NASDAQ:CAPR) Given Average Recommendation of “Buy” by Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have earned an average rating of “Buy” from the five research firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $22.60.

A number of equities research analysts have recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Maxim Group boosted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $20.51 on Friday. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $23.40. The business has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $6.26. The stock has a market capitalization of $655.89 million, a PE ratio of -23.57 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. As a group, sell-side analysts expect that Capricor Therapeutics will post -1.13 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the last quarter. Renaissance Technologies LLC raised its stake in Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares during the last quarter. Marshall Wace LLP acquired a new position in Capricor Therapeutics in the second quarter valued at $426,000. Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Capricor Therapeutics during the 2nd quarter worth about $147,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.